Global analysis and trajectory of the epidemiology of schizophrenia 2018-2030 | News


DUBLIN, December 31, 2021 / PRNewswire / – “Schizophrenia – Epidemiological Forecast to 2030” drug pipelines have been added to offer.

This report provides an in-depth understanding of the disease, historical and predicted epidemiology of schizophrenia in United States, UE5 (Germany, Spain, Italy, France, and UK) and Japan.

Epidemiological perspective

The disease epidemiology covered in the report provides a historical and predictive epidemiology segmented by prevalent cases of schizophrenia, prevalent cases diagnosed with schizophrenia, prevalent cases diagnosed with schizophrenia by sex, prevalent cases diagnosed with schizophrenia by age and by gravity. Prevalent cases of schizophrenia scenario in 7MM coverage United States, EU5 countries (Germany, France, Italy, Spain, and UK) and Japan from 2017 to 2030.

Segmentation of epidemiology

  • The total prevalent schizophrenia population in 7MM was 5,969,144 in 2020. These cases of schizophrenia in 7MM are expected to increase throughout the study period, i.e. 2018-2030.
  • The total prevalent population diagnosed with schizophrenia in 7MM was 3,043,148 in 2020.
  • Among the five European countries, Germany has the highest prevalent diagnosed population, followed by the UK and France. On the other hand, Spain had the lowest diagnosed prevalent population.
  • In the epidemiological model of schizophrenia, there are several referred age groups ranging from 18 to 24 years; 25-34 years old; 35-44 years; 45-54 years old; 55-64 years and 65+ years for schizophrenia in the United States. The highest was 371,697 in the 35-44 age group, in 2020, in the United States.
  • Men with schizophrenia appear to have more negative symptoms and more severe clinical features than women, especially when it comes to social withdrawal, substance abuse, and blunt or incongruous effects than women.
  • In 2020, the prevalent population diagnosed with mild schizophrenia was 317,745, which represented 22.00% of the total cases diagnosed with schizophrenia, in United States.

According to the editor, the majority of schizophrenia cases are men compared to women, in the US and in the EU-5. But in Japan female diagnosed cases represent the majority of cases.

Scope of the report

  • The report covers a descriptive overview of schizophrenia, explaining its causes, signs and symptoms, pathophysiology, and currently available therapies.
  • Report provides insight into historic and forecasted 7MM patient pool coverage United States, EU5 countries (Germany, France, Italy, Spain, and UK) and Japan.
  • The report assesses the risk and burden of the disease and highlights the unmet needs of schizophrenia.
  • The report provides the disease epidemiology segmentation for 7 MM by total number of prevalent cases of schizophrenia, total number of cases of schizophrenia diagnosed and treated.

Highlights of the report

  • 10-year forecast of schizophrenia
  • 7MM coverage
  • Prevalent cases of schizophrenia in 7MM
  • Diagnosed prevalent cases of schizophrenia in 7MM
  • Prevalent cases of schizophrenia diagnosed by sex in 7 MM
  • Prevalent cases of schizophrenia diagnosed by age in 7 MM
  • Severity specific Diagnosed prevalent cases of schizophrenia in 7 MM

Answers to key questions

  • What are the disease risk, burden, and unmet needs of schizophrenia?
  • What is the historical pool of patients with schizophrenia in United States, UE5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan?
  • What would be the expected schizophrenic patient pool at the 7 MM level?
  • What will be the growth opportunities in the 7MM in terms of the schizophrenia patient population?
  • Among the countries mentioned above, which country would have the highest prevalence of schizophrenia during the forecast period (2021-2030)?
  • At what CAGR is the population expected to grow over the 7 MM during the forecast period (2021-2030)?

Reasons to buy

  • Develop business strategies by understanding the trends shaping and driving the 7MM Schizophrenia market.
  • The Schizophrenia Epidemiology Report and Model was written and developed by master’s and doctoral level epidemiologists.
  • The schizophrenia epidemiology model developed by the publisher is easy to navigate, interactive with dashboards and epidemiology based on transparent and consistent methodologies. Additionally, the model supports the data presented in the report and presents disease trends over the 10-year forecast period using reliable sources.

Key topics covered

1 key information

2 Presentation of the report

3 Executive summary of schizophrenia

4 Background and overview of the disease

4.1 Presentation

4.2 Warning signs and symptoms of schizophrenia

4.3 Risk factors for schizophrenia

4.4 Schizophrenia subtypes

4.5 Mechanism of schizophrenia

4.6 Genetics of schizophrenia

4.7 Diagnosis

4.8 Differential diagnosis

4.9 Processing and management

4.9.1 Symptoms in the acute phase Assessment before treatment

4.9.2 Drug (antipsychotic)

4.9.3 Psychotherapy

4.9.4 Psychosocial therapy

4.9.5 Electroconvulsive therapy (ECT)

4.9.6 IPAP algorithm for schizophrenia

4.9.7 Processing guidelines The American Psychiatric Association (APA) Practice Guideline for the Treatment of Patients with Schizophrenia The Schizophrenia Patient Outcomes Research (PORT) Team: Updated Treatment Recommendations Updated recommendations for the treatment of port in schizophrenia: recommendations for psychosocial treatment

5 Epidemiology and patient population

5.1 Main findings

5.2 Epidemiological methodology

5.3 Total prevalent cases of schizophrenia in the 7MM

5.4 Total prevalent cases diagnosed with schizophrenia in the 7MM

5.5 United States epidemiology

5.5.1 Assumptions and rationale

5.5.2 Prevalent cases of schizophrenia in United States

5.5.3 Prevalent cases diagnosed with schizophrenia in United States

5.5.4 Prevalent cases diagnosed by sex of schizophrenia in United States

5.5.5 Diagnosed by age Prevailing cases of schizophrenia in United States

5.5.6 According to the severity diagnosed Prevailing cases of schizophrenia in United States

5.6 UE5 Epidemiology

5.7 Epidemiology of Japan

6 views KOL

7 Annex

7.1 Bibliography

7.2 Methodology of the report

For more information on this Drug Pipeline Report, visit

Media contact:

Research and markets

Laura Wood, senior

[email protected]

For EST office hours, call + 1-917-300-0470

For USA / CAN call toll free + 1-800-526-8630

For GMT office hours, call + 353-1-416-8900

US Fax: 646-607-1904

Fax (outside the United States): + 353-1-481-1716

View original content:

SOURCE Research and Markets

Source link

Comments are closed.